Amjad Mohammad Asim, Hamid Zamara, Patel Yamini, Husain Mujtaba, Saddique Ammad, Liaqat Adnan, Ochieng Pius
Internal Medicine, The Wright Center for Graduate Medical Education, Scranton, USA.
Medicine, Shifa International Hospital, Islamabad, PAK.
Cureus. 2022 May 30;14(5):e25493. doi: 10.7759/cureus.25493. eCollection 2022 May.
All modern vaccines share the risk of neurological adverse effects. Only a few cases of Parsonage-Turner syndrome (PTS), an uncommon peripheral nerve condition associated with coronavirus disease 2019 (COVID-19) immunization, have been reported to date. We describe a case of COVID-19 vaccine-induced PTS and provide a brief literature review. A 78-year-old male non-smoker with a medical history of coronary artery disease presented with non-exertional, constant chest pain for one hour and new onset of bilateral hand weakness for three days. He had no neurological disease or allergies and denied any recent trauma or infection. Three weeks before the onset of the symptoms, the patient received a second dose of the BNT162b2 COVID-19 vaccine, which was administered 21 days after the first dose. Physical examination was significant for weakness in right-hand grip and wrist flexion. There were no other motor deficits, upper motor neuron signs, bulbar weakness, or sensory deficits. Diagnostic workup for the underlying diabetes mellitus, infections, or other autoimmune diseases was negative. Imaging workup revealed no demyelination, fracture deformity, traumatic subluxation, or compressive myelopathy. Nerve conduction studies, including needle electromyography, showed decreased motor unit recruitment in the bilateral first dorsal interosseous and right deltoid, biceps, and triceps muscles confirming PTS. The patient was treated with 40 mg/day of oral prednisone and occupational therapy to maintain range of motion and activities of daily living. PTS is also known as neuralgic amyotrophy, brachial plexus neuritis, brachial plexopathy, and shoulder-girdle syndrome. It is characterized by asymmetrical, chronic, resistant upper extremity neuropathic pain and neurological defects such as paralysis and paresthesia. There are two different types of PTS: non-hereditary and inherited. The etiology and pathophysiology of PTS are not fully understood. Various aspects such as genetic, environmental, and immunological predisposition may play a role in developing the syndrome. Infections, vaccines, and injuries are typical causes of non-hereditary forms. After the COVID-19 epidemic and the commencement of a global immunization effort, similar instances happened. Presently there is no available test that unequivocally confirms or excludes PTS itself. Electrodiagnostic study and imaging modalities help to rule out other differential diagnoses. Also, there is no specific treatment available; however, it may resolve independently of treatment with supportive care.
所有现代疫苗都存在神经不良反应风险。截至目前,仅报告了少数几例与2019冠状病毒病(COVID-19)免疫接种相关的罕见周围神经疾病——帕森奇-特纳综合征(PTS)病例。我们描述了一例由COVID-19疫苗诱导的PTS病例,并进行简要文献综述。一名78岁男性非吸烟者,有冠状动脉疾病病史,出现非劳力性持续性胸痛1小时,双侧手部无力新发3天。他无神经疾病或过敏史,否认近期有任何外伤或感染。在症状出现前三周,患者接种了第二剂BNT162b2 COVID-19疫苗,第一剂接种后21天接种了该剂疫苗。体格检查发现右手握力和腕部屈曲无力明显。无其他运动功能缺损、上运动神经元体征、延髓肌无力或感觉缺损。对潜在糖尿病、感染或其他自身免疫性疾病的诊断检查结果为阴性。影像学检查未发现脱髓鞘、骨折畸形、创伤性半脱位或压迫性脊髓病。神经传导研究,包括针极肌电图检查,显示双侧第一背侧骨间肌以及右侧三角肌、肱二头肌和肱三头肌运动单位募集减少,确诊为PTS。患者接受了每日40毫克的口服泼尼松治疗以及职业治疗,以维持关节活动范围和日常生活活动能力。PTS也被称为神经痛性肌萎缩、臂丛神经炎、臂丛病变和肩带综合征。其特征为不对称、慢性、难治性上肢神经性疼痛以及诸如瘫痪和感觉异常等神经缺陷。PTS有两种不同类型:非遗传性和遗传性。PTS的病因和病理生理学尚未完全明确。遗传、环境和免疫易感性等各个方面可能在该综合征的发生中起作用。感染、疫苗和损伤是非遗传性PTS的典型病因。在COVID-19疫情及全球免疫接种工作开始后,出现了类似病例。目前尚无明确确诊或排除PTS本身的可用检测方法。电诊断研究和影像学检查有助于排除其他鉴别诊断。此外,目前没有特效治疗方法;不过,在支持性治疗下它可能自行缓解。